688578 艾力斯
已收盘 11-19 15:00:00
资讯
新帖
简况
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症纳入国家医保目录的公告》
证券之星 · 11-17
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症纳入国家医保目录的公告》
艾力斯(688578.SH):甲磺酸伏美替尼片新增适应症纳入国家医保目录
智通财经 · 11-15
艾力斯(688578.SH):甲磺酸伏美替尼片新增适应症纳入国家医保目录
艾力斯(688578)11月10日主力资金净卖出3506.05万元
证券之星 · 11-11
艾力斯(688578)11月10日主力资金净卖出3506.05万元
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001获得药物临床试验批准通知书的公告》
证券之星 · 11-09
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001获得药物临床试验批准通知书的公告》
艾力斯(688578)11月6日主力资金净买入355.43万元
证券之星 · 11-07
艾力斯(688578)11月6日主力资金净买入355.43万元
艾力斯最新公告:注射用AST1001获药物临床试验批准通知书
证券之星 · 11-06
艾力斯最新公告:注射用AST1001获药物临床试验批准通知书
艾力斯(688578)披露公司仲裁事项进展公告,11月05日股价上涨0.94%
证券之星 · 11-05
艾力斯(688578)披露公司仲裁事项进展公告,11月05日股价上涨0.94%
争议仲裁落定,艾力斯需向复星曜泓支付逾5000万元,前期已计提1880万元
每日经济新闻 · 11-04
争议仲裁落定,艾力斯需向复星曜泓支付逾5000万元,前期已计提1880万元
艾力斯:与复星曜泓仲裁事项已作出终局裁决
格隆汇 · 11-04
艾力斯:与复星曜泓仲裁事项已作出终局裁决
艾力斯(688578)披露将参加2026年上海辖区上市公司三季报集体业绩说明会,11月03日股价上涨0.78%
证券之星 · 11-03
艾力斯(688578)披露将参加2026年上海辖区上市公司三季报集体业绩说明会,11月03日股价上涨0.78%
中邮证券:给予艾力斯买入评级
证券之星 · 11-03
中邮证券:给予艾力斯买入评级
艾力斯(688578)披露以集中竞价交易方式回购公司股份的进展公告,11月02日股价上涨1.78%
证券之星 · 11-02
艾力斯(688578)披露以集中竞价交易方式回购公司股份的进展公告,11月02日股价上涨1.78%
艾力斯(688578)10月29日主力资金净卖出2553.03万元
证券之星 · 10-30
艾力斯(688578)10月29日主力资金净卖出2553.03万元
图解艾力斯三季报:第三季度单季净利润同比增长40.38%
证券之星 · 10-28
图解艾力斯三季报:第三季度单季净利润同比增长40.38%
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001临床试验申请获得FDA批准的公告》
证券之星 · 10-26
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001临床试验申请获得FDA批准的公告》
艾力斯(688578)10月23日主力资金净卖出2397.57万元
证券之星 · 10-24
艾力斯(688578)10月23日主力资金净卖出2397.57万元
艾力斯最新公告:注射用AST1001临床试验申请获FDA批准
证券之星 · 10-23
艾力斯最新公告:注射用AST1001临床试验申请获FDA批准
艾力斯(688578)10月22日主力资金净卖出1902.27万元
证券之星 · 10-23
艾力斯(688578)10月22日主力资金净卖出1902.27万元
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告》
证券之星 · 10-21
股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告》
司美格鲁肽注射液在华获批48小时配送新条件;艾力斯首次回购近1411万元|医药早参
每日经济新闻 · 10-20
司美格鲁肽注射液在华获批48小时配送新条件;艾力斯首次回购近1411万元|医药早参
加载更多
公司概况
公司名称:
上海艾力斯医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-02
主营业务:
上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。2025年,公司自主研发的1类小分子靶向药物甲磺酸伏美替尼片的核心化合物专利创新技术(吡啶胺基嘧啶衍生物、其制备方法及应用)已荣获国家知识产权局、世界知识产权组织联合颁授的第二十五届中国专利金奖。
发行价格:
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":82.17,"timestamp":1795071600000,"preClose":78.99,"halted":0,"volume":5889524,"delay":0,"changeRate":0.0403,"floatShares":450000000,"shares":450000000,"eps":6.4592,"marketStatus":"已收盘","change":3.18,"latestTime":"11-19 15:00:00","open":78.7,"high":82.66,"low":78.48,"amount":478000000,"amplitude":0.0529,"askPrice":82.18,"askSize":41,"bidPrice":82.17,"bidSize":36,"shortable":0,"etf":0,"ttmEps":6.4592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795138200000},"marketStatusCode":5,"adr":0,"adjPreClose":78.99,"symbolType":"stock_kcb","openAndCloseTimeList":[[1795051800000,1795059000000],[1795064400000,1795071600000]],"highLimit":86.89,"lowLimit":71.09,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":4.13,"roa":"--","peRate":12.72139,"roe":"28.65%","epsLYR":4.86,"committee":-0.207547,"marketValue":36977000000,"turnoverRate":0.0131,"status":0,"afterMarket":{"amount":165326.04,"volume":2012,"close":82.17,"buyVolume":0,"sellVolume":62,"time":1795073637746,"indexStatus":"已收盘 11-19 15:30:00","preClose":78.99},"floatMarketCap":36977000000},"requestUrl":"/m/hq/s/688578","defaultTab":"news","newsList":[{"id":"2684649447","title":"股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症纳入国家医保目录的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684649447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684649447?lang=zh_cn&edition=full","pubTime":"2026-11-17 01:07","pubTimestamp":1794848836,"startTime":"0","endTime":"0","summary":"公司公告汇总:甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症被新增纳入《国家基本医疗保险、生育保险和工伤保险药品目录》,协议有效期为2027年1月1日至2027年12月31日。该适应症适用于既往经含铂化疗治疗时或治疗后出现疾病进展,或不耐受含铂化疗,并经检测确认存在EGFR 20号外显子插入突变的局部晚期或转移性NSCLC成人患者。伏美替尼一线及其他二线治疗适应症在原协议期内继续有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700000861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","688578","BK1161","09939","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683169655","title":"艾力斯(688578.SH):甲磺酸伏美替尼片新增适应症纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683169655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683169655?lang=zh_cn&edition=full","pubTime":"2026-11-15 15:55","pubTimestamp":1794729355,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯 发布公告,公司产品甲磺酸伏美替尼片EGFR 20号外显子插入突变非小细胞肺癌二线治疗适应症被新增纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。据悉,甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂,为公司自主研发的1类新药,属于小分子靶向药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682328516","title":"艾力斯(688578)11月10日主力资金净卖出3506.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682328516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682328516?lang=zh_cn&edition=full","pubTime":"2026-11-11 08:33","pubTimestamp":1794357231,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月10日收盘,艾力斯报收于84.26元,下跌0.99%,换手率0.97%,成交量4.38万手,成交额3.71亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入2630.23万元,融资偿还3364.01万元,融资净偿还733.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100013586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682826951","title":"股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682826951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682826951?lang=zh_cn&edition=full","pubTime":"2026-11-09 03:38","pubTimestamp":1794166691,"startTime":"0","endTime":"0","summary":"公司公告汇总上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001获得药物临床试验批准通知书的公告上海艾力斯医药科技股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,公司自主研发的注射用AST1001用于治疗既往经标准治疗失败的局部晚期或转移性实体瘤成人患者的I期临床研究获得批准。此前,该药物已于2026年10月获美国FDA批准开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900001021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688578","BK1574","BK1515","159938","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681818230","title":"艾力斯(688578)11月6日主力资金净买入355.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681818230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681818230?lang=zh_cn&edition=full","pubTime":"2026-11-07 09:00","pubTimestamp":1794013218,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月6日收盘,艾力斯报收于87.47元,上涨0.77%,换手率1.61%,成交量7.25万手,成交额6.41亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入3820.61万元,融资偿还4356.93万元,融资净偿还536.33万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700010057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681862239","title":"艾力斯最新公告:注射用AST1001获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681862239","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681862239?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:12","pubTimestamp":1793974346,"startTime":"0","endTime":"0","summary":"艾力斯(688578.SH)公告称,公司近日收到国家药监局核准签发的《药物临床试验批准通知书》,自主研发的注射用AST1001用于治疗既往经标准治疗失败的局部晚期或转移性实体瘤成人患者I期临床研究获得药物临床试验批准。AST1001是公司自主研发的抗体偶联药物,由靶向EGFR和c-MET的双特异性抗体与拓扑异构酶Ⅰ抑制剂有效载荷-连接子偶联而成。该药品对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600036684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681028398","title":"艾力斯(688578)披露公司仲裁事项进展公告,11月05日股价上涨0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681028398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681028398?lang=zh_cn&edition=full","pubTime":"2026-11-05 18:08","pubTimestamp":1793873327,"startTime":"0","endTime":"0","summary":"截至2026年11月5日收盘,艾力斯报收于86.8元,较前一交易日上涨0.94%,最新总市值为390.6亿元。该股当日开盘85.63元,最高88.08元,最低85.6元,成交额达5.42亿元,换手率为1.39%。上海艾力斯医药科技股份有限公司于近日发布《关于公司仲裁事项进展的公告》。上述款项应于裁决生效之日起十五日内支付完毕。公司已于2023年底计提相关费用合计18,800,047.34元。本次仲裁裁决预计不会对公司财务状况和经营成果产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500032576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680575580","title":"争议仲裁落定,艾力斯需向复星曜泓支付逾5000万元,前期已计提1880万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680575580","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680575580?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:06","pubTimestamp":1793801160,"startTime":"0","endTime":"0","summary":"此次裁决为终局裁决纠纷缘起于2022年。裁决结果共八项。折算后,各项合计5042.62万元。裁决书同时认定,《独家推广协议》及其补充协议已于2024年1月1日解除。计提方面,公告显示,公司已于2023年底就该事项计提推广服务费1680万元、保证金返还200万元,合计1880万元。截至9月30日,总资产100.57亿元,较上年度末增长27.23%,归属于上市公司股东的所有者权益89.49亿元,增长26.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-11-04/doc-inixqsyw6706977.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-11-04/doc-inixqsyw6706977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680319620","title":"艾力斯:与复星曜泓仲裁事项已作出终局裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=2680319620","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680319620?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:59","pubTimestamp":1793786357,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680722777","title":"艾力斯(688578)披露将参加2026年上海辖区上市公司三季报集体业绩说明会,11月03日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680722777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680722777?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:07","pubTimestamp":1793714835,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘,艾力斯报收于83.08元,较前一交易日上涨0.78%,最新总市值为373.86亿元。该股当日开盘82.46元,最高84.0元,最低80.49元,成交额达5.31亿元,换手率为1.43%。公告显示,公司将于2026年11月12日15:00-16:30参加2026年上海辖区上市公司三季报集体业绩说明会,通过上证路演中心网络文字互动方式与投资者交流。会议将围绕公司2026年第三季度及前三季度的经营成果、财务状况等事项进行沟通。说明会结束后可通过上证路演中心查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300045013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680216137","title":"中邮证券:给予艾力斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680216137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680216137?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:02","pubTimestamp":1793710953,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对艾力斯进行研究并发布了研究报告《伏美替尼环比增速稳定,净利率同比提升》,给予艾力斯买入评级。公司深耕肺癌市场,商业化成绩显著,考虑伏美替尼仍有20外插与辅助治疗等适应症拓展空间,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级9家,增持评级2家。本文数据来源于中邮证券有限责任公司,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300042406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680869763","title":"艾力斯(688578)披露以集中竞价交易方式回购公司股份的进展公告,11月02日股价上涨1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680869763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680869763?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:03","pubTimestamp":1793628183,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘,艾力斯报收于82.44元,较前一交易日上涨1.78%,最新总市值为370.98亿元。近日,上海艾力斯医药科技股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示,公司于2026年10月13日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购期限为2026年10月13日至2027年4月12日,拟回购金额不低于1亿元且不超过2亿元,回购价格不超过150元/股。本次回购股份用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200036315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679557622","title":"艾力斯(688578)10月29日主力资金净卖出2553.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679557622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679557622?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:17","pubTimestamp":1793319437,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月29日收盘,艾力斯报收于83.03元,上涨2.14%,换手率1.21%,成交量5.46万手,成交额4.47亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入2170.14万元,融资偿还4100.94万元,融资净偿还1930.8万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000014922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678353102","title":"图解艾力斯三季报:第三季度单季净利润同比增长40.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678353102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678353102?lang=zh_cn&edition=full","pubTime":"2026-10-28 01:14","pubTimestamp":1793121249,"startTime":"0","endTime":"0","summary":"证券之星消息,艾力斯2026年三季报显示,前三季度公司主营收入51.35亿元,同比上升37.57%;归母净利润23.33亿元,同比上升44.41%;扣非净利润21.34亿元,同比上升47.04%;其中2026年第三季度,公司单季度主营收入18.16亿元,同比上升33.58%;单季度归母净利润7.92亿元,同比上升40.38%;单季度扣非净利润7.68亿元,同比上升40.5%;负债率11.02%,投资收益969.57万元,财务费用-5141.1万元,毛利率94.89%。财报数据概要请见下图:本文数据来源于艾力斯2026年三季报,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800002585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136860","title":"股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001临床试验申请获得FDA批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136860?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:44","pubTimestamp":1792950255,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,艾力斯报收于88.12元,上涨4.28%,换手率1.69%,成交量7.63万手,成交额6.59亿元。公司公告汇总上海艾力斯医药科技股份有限公司自愿披露关于注射用AST1001临床试验申请获得FDA批准的公告上海艾力斯医药科技股份有限公司自主研发的注射用AST1001获得美国FDA批准开展临床试验。本次获批的临床试验为全球多中心、开放标签、剂量递增和扩展的I期试验,旨在评估药物的安全性、耐受性、药代动力学及初步抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","688578","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677903178","title":"艾力斯(688578)10月23日主力资金净卖出2397.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677903178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677903178?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:22","pubTimestamp":1792801328,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月23日收盘,艾力斯报收于88.12元,上涨4.28%,换手率1.69%,成交量7.63万手,成交额6.59亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入4200.95万元,融资偿还6812.45万元,融资净偿还2611.5万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922214","title":"艾力斯最新公告:注射用AST1001临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922214?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:39","pubTimestamp":1792759175,"startTime":"0","endTime":"0","summary":"艾力斯(688578.SH)公告称,公司近日收到美国食品药品监督管理局(FDA)关于同意开展注射用AST1001用于治疗既往经标准治疗失败的局部晚期或转移性实体瘤成人患者临床试验的函告。该药品是公司自主研发的抗体偶联药物,由靶向EGFR和c-MET的双特异性抗体与拓扑异构酶Ⅰ抑制剂有效载荷-连接子偶联而成。本次获批是公司新药研发的阶段性成果,对近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300041838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677491814","title":"艾力斯(688578)10月22日主力资金净卖出1902.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677491814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677491814?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:20","pubTimestamp":1792714842,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月22日收盘,艾力斯报收于84.5元,下跌0.05%,换手率1.21%,成交量5.43万手,成交额4.6亿元。近5日资金流向一览见下表:艾力斯融资融券信息显示,融资方面,当日融资买入1854.26万元,融资偿还5934.42万元,融资净偿还4080.16万元。艾力斯主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677112618","title":"股市必读:艾力斯新发布《上海艾力斯医药科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677112618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677112618?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:21","pubTimestamp":1792516868,"startTime":"0","endTime":"0","summary":"公司公告汇总上海艾力斯医药科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告2026年10月19日,公司通过集中竞价交易方式首次回购股份169,956股,占公司总股本的0.038%;回购最高价83.97元/股,最低价81.61元/股;已支付金额14,110,147.52元。上海艾力斯医药科技股份有限公司关于回购股份事项前十名股东和前十名无限售条件股东的公告公司于2026年10月13日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK0239","BK1161","09939","688578","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676634627","title":"司美格鲁肽注射液在华获批48小时配送新条件;艾力斯首次回购近1411万元|医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2676634627","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676634627?lang=zh_cn&edition=full","pubTime":"2026-10-20 07:00","pubTimestamp":1792450857,"startTime":"0","endTime":"0","summary":"|2026年10月20日星期二|NO.1司美格鲁肽注射液在华获批48小时配送新条件10月19日,诺和诺德宣布,中国国家药监局已批准更新司美格鲁肽注射液(商品名:诺和盈?)产品信息:在分发给患者的过程中,首次开启前,诺和盈?可在2℃~30℃的温度下储存最长48小时。此次批准使诺和盈?成为中国首个且唯一具备这一配送灵活性的GLP-1体重管理治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610203900358225.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610203900358225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09939","BK1515","688578","BK1161","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795117356303,"stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0276},{"period":"3month","weight":-0.2907},{"period":"6month","weight":-0.0984},{"period":"1year","weight":-0.1412},{"period":"ytd","weight":-0.2013}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0422},{"period":"3month","weight":-0.0839},{"period":"6month","weight":-0.1301},{"period":"1year","weight":-0.0935},{"period":"ytd","weight":-0.0986}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23194人(较上一季度增加10.24%)","perCapita":"19401股","listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","registeredCapital":"45000万元","survey":" 上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。2025年,公司自主研发的1类小分子靶向药物甲磺酸伏美替尼片的核心化合物专利创新技术(吡啶胺基嘧啶衍生物、其制备方法及应用)已荣获国家知识产权局、世界知识产权组织联合颁授的第二十五届中国专利金奖。","listedPrice":22.73},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}